Kennedy Airport’s international mail facilities occupy Ozempic, Wegovy and other weight loss pills.
NebraskaDailyNews
Copenhagen, Denmark – Europe’s pharmaceutical sector is having potential impacts on the scope exemption of U.S. President Donald Trump Fade to achieve the potential impact of U.S. tariffs.
So far, the pharmaceutical industry has exempted trade taxes, but Trump confirmed last week that he will soon impose tariffs on the industry.
Currently, drugmakers are lobbying for the president to rank Report On Tuesday, four sources familiar with the discussion were cited. The levy may not be announced on Wednesday, but may be inevitable, sources said.
Gradually imposed tariffs on the industry can reduce immediate financial blows and give companies time to relocate their manufacturing sector in the United States. However, some companies warn that a lack of clarity is already having a negative impact.
“For us, it’s the impact of tariffs, and its impact on the market,” Ester Baiget, CEO of Danish biotechnology company Novonesis, told NebraskaDailyNews on Tuesday.
“When you bring tariffs, it causes uncertainty, and when you () are uncertain, you stop, stop innovate, release launches, you stop investing,” Beggart said. About 30%It comes from sales in the United States, but has also been promoting its manufacturing industry in the country.
Denmark
The chairman of Novo Nordisk told NebraskaDailyNews last week that the company was not speculating before Trump’s tariff announcement, but focused on maintaining flexibility.
“It doesn’t make sense to speculate too much,” Chairman Helge Lund told NebraskaDailyNews, arguing by the Danish pharmaceutical giant’s annual shareholders’ meeting. “We focus on what we will affect.”
Still, the inquiry was asked about how tariffs affect U.S. sales of the popular obesity and diabetes treatments for Novo and its impact on U.S. competitors and Zepbough-Maker-Maker Eli Lilly. Lund won’t comply with its share of weight loss medication sales
‘No. 1 Questions about investors’ thoughts
The threat of tariffs has also increased uncertainty in the investment landscape. Emily Field, head of Barclays European Medicines Research, spoke on NebraskaDailyNews on Monday, saying the tariffs were “the number one question about the minds of investors.”
Denmark’s Minister of Industry, Commerce and Financial Affairs Morten Bødskov told NebraskaDailyNews on Tuesday that he is liaisoning with the country’s pharmaceutical industry and businesses to talk more broadly about the potential impact of tariffs on a small, export-heavy economy.
“Of course, we’re having close conversations with them,” Bødskov said, adding: “Our job is to let them discuss how the world changes. Many of them are world-leading companies, so it’s our job to help them understand the perspective of the market in the future.”
However, he noted that it is unclear whether the Trump administration can convince its trade protectionist policies or provide subsidies to certain sectors.
Meanwhile, Baiget said it was a “very close” viewing issue and ready to take action when needed.
“There is a lot of volatility and there are a lot of fast and moving trends,” she said. “We cut it open and we learn how to ease some of it.”
(tagstotranslate) Healthcare Industry (T) Copenhagen (T) Donald Trump (T) Denmark (T) United States (T) United States (T) Bavaria Nordic A/S (T) Bavaria Nordic North European A/S (T) Lilly Drn (T) Lilly DRN (T) Pharmaceuticals (T) Biotechnology and Pharmaceuticals (T)
